- $9.07m
- $15.23m
- $0.07m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 91.93 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -7427.33% | ||
Financial Summary
| Year End 31st Aug | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 0.01 | 0.17 | 0.07 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Allied Corp. is a Canadian cannabis supplier with its production center in Colombia. It is focused on the development of Colombian produced medicinal cannabis for patients with conditions potentially suitable for treatment. Such conditions include anxiety, insomnia, anorexia, chronic pain, epilepsy, chemotherapy-induced nausea and vomiting, post-traumatic stress disorder, Parkinson's disease, Tourette's syndrome, irritable bowel syndrome and spasticity associated with multiple sclerosis and spinal cord injury. Its core hemp derived cannabidiol (CBD) brands are Tactical Relief Brand, Equilibrium Bio and MaXXa. Liberty, Tactical Relief brand's flagship product, is a hemp derived CBD tincture for sale in the United States. Equilibrium Bio brand is primarily focused on hydration and recovery areas. MaXXa brand develops natural CBD infused cosmetics and beauty products. Its subsidiaries include AM Biosciences, Allied US Products LLC, Tactical Relief LLC, Baleno Ltd. and Allied Colombia.
Directors
- Last Annual
- August 31st, 2023
- Last Interim
- May 31st, 2024
- Incorporated
- February 3rd, 2013
- Public Since
- December 4th, 2018
- No. of Shareholders
- 3,062
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 105,816,904
- Address
- SUITE 200-460 DOYLE AVE, KELOWNA, V1Y OC2
- Web
- https://allied.health/
- Phone
- +1 7783885258
- Auditors
- Manning Elliott LLP
Upcoming Events for ALID
Similar to ALID
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 19:11 UTC, shares in Allied are trading at $0.09. This share price information is delayed by 15 minutes.
Shares in Allied last closed at $0.09 and the price had moved by -48.06% over the past 365 days. In terms of relative price strength the Allied share price has underperformed the S&P500 Index by -59.47% over the past year.
There is no consensus recommendation for this security.
Find out moreAllied does not currently pay a dividend.
Allied does not currently pay a dividend.
Allied does not currently pay a dividend.
To buy shares in Allied you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.09, shares in Allied had a market capitalisation of $9.07m.
Here are the trading details for Allied:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ALID
Based on an overall assessment of its quality, value and momentum Allied is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Allied. Over the past six months, its share price has underperformed the S&P500 Index by -48.74%.
As of the last closing price of $0.09, shares in Allied were trading -16.48% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Allied PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Allied's management team is headed by:
- Calum Hughes - CHM
- Ryan Maarschalk - CFO
- Paul Bullock - COO
- Jim Smeeding - VPR
- Jay Mcmillan - OTH